[

covaxin

]

WHO to consider Covaxin's emergency listing in meet today

WHO has said it “cannot cut corners” to recommend Covaxin’s inclusion in the EUL for vaccination against Covid-19. The agency said last week it was expecting one additional piece of information from the Covaxin manufacturer, which has been submitting data on a rolling basis.
A health worker prepares a dose of the Covaxin Covid-19 vaccine at a vaccination center set up at a Delhi government health dispensary in New Delhi, India. (Bloomberg)
A health worker prepares a dose of the Covaxin Covid-19 vaccine at a vaccination center set up at a Delhi government health dispensary in New Delhi, India. (Bloomberg)
Published on Oct 26, 2021 05:31 AM IST
Copy Link
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi

‘Phase 2 trials almost completed’: Dr Krishna Ella on nasal Covid-19 vaccine

The vaccine has shown ‘good results,’ the Bharat Biotech chairman and MD said, echoing Dr VK Paul's remarks from last month.
A health worker collects swab samples for Covid-19 tests in Nagpur, Maharashtra. (PTI)
A health worker collects swab samples for Covid-19 tests in Nagpur, Maharashtra. (PTI)
Published on Oct 23, 2021 04:06 PM IST
Copy Link
By hindustantimes.com, New Delhi

As Covaxin awaits nod, WHO official says, ‘it takes longer sometimes’

Earlier this week, the international public health body had said that it “cannot cut corners” to recommend Covaxin’s inclusion in the EUL for vaccination against Covid-19.
Covid-19: A health worker prepares a dose of Covaxin at a vaccination center set up at a Delhi government health dispensary. (File Photo / Bloomberg)
Covid-19: A health worker prepares a dose of Covaxin at a vaccination center set up at a Delhi government health dispensary. (File Photo / Bloomberg)
Updated on Oct 22, 2021 01:15 PM IST
Copy Link
Written by Joydeep Bose | Edited by Sohini Goswami, Hindustan Times, New Delhi

Awaiting more information on Covaxin: WHO

  • The WHO’s nod for Covaxin’s emergency use authorisation is necessary for its widespread acceptability as a safe and effective vaccine.
The UN health agency said it is expecting one additional piece of information from Covaxin manufacturer, Bharat Biotech, which has been submitting data to the WHO on a rolling basis.
The UN health agency said it is expecting one additional piece of information from Covaxin manufacturer, Bharat Biotech, which has been submitting data to the WHO on a rolling basis.
Published on Oct 19, 2021 12:27 AM IST
Copy Link
By HT Correspondent, Hindustan Times, New Delhi

WHO to meet on Oct 26 to consider Covaxin's emergency listing

  • With this recent development, India can now expect the Emergency Use approval for Covaxin by the last week of October.
On October 5, the world health body extended giving the EUL to Covaxin by a week. (File photo)
On October 5, the world health body extended giving the EUL to Covaxin by a week. (File photo)
Updated on Oct 17, 2021 10:50 PM IST
Copy Link
Written by Shubhangi Gupta | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

DCGI yet to approve Covaxin’s emergency use in children

For the vaccine to be included formally in the government’s coronavirus immunisation campaign for children, DCGI’s approval is mandatory.
The DCGI is yet to approve Bharat Biotech’s coronavirus vaccine Covaxin for emergency use in children despite a recommendation from the Subject Expert Committee (SEC) earlier in the week. (PTI)
The DCGI is yet to approve Bharat Biotech’s coronavirus vaccine Covaxin for emergency use in children despite a recommendation from the Subject Expert Committee (SEC) earlier in the week. (PTI)
Updated on Oct 16, 2021 04:42 AM IST
Copy Link
By Rhythma Kaul, Hindustan Times, New Delhi

TN to become first in country to administer Covid shots to children over 2 years

Ma Subramanian said that once the Tamil Nadu state government gets the nod from the Centre regarding the inoculation of the vaccine, the state would be the first to do so.
52,379,870 doses of the vaccine have been administered in Tamil Nadu till 7am on Wednesday.(AP | Representational image)
52,379,870 doses of the vaccine have been administered in Tamil Nadu till 7am on Wednesday.(AP | Representational image)
Published on Oct 13, 2021 10:07 PM IST
Copy Link
Written by Srivatsan K C | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

Covaxin gets emergency use nod for kids: Here's what experts have to say

  • Health experts have welcomed the move saying it will be beneficial for children and help them resume normal lives but added that there is a need to establish its efficacy globally.
Bharat Biotech was granted approval for conducting Covaxin trials in children back in May.(AP)
Bharat Biotech was granted approval for conducting Covaxin trials in children back in May.(AP)
Published on Oct 13, 2021 03:48 PM IST
Copy Link
By hindustantimes.com | Edited by Parmita Uniyal

Covid-19 vaccine for children: These four are on the horizon

Union minister of state for health and family welfare Bharati Pravin Pawar on Tuesday said that evaluation of Covid-19 vaccine for children is under progress. The final approval will be given by the Drugs Controller General of India.
Covaxin clinical trials data of 2-18 years age group has been submitted to Central Drugs Standard Control Organisation.(HT Photo)
Covaxin clinical trials data of 2-18 years age group has been submitted to Central Drugs Standard Control Organisation.(HT Photo)
Updated on Oct 13, 2021 09:22 AM IST
Copy Link
By hindustantimes.com, Hindustan Times, New Delhi

Covaxin gets SEC emergency use nod for children between 2-18 years of age

  • Bharat Biotech, the Hyderabad based biotechnology company, submitted data from Covaxin's trial in children aged 2 to 18 years to the DCGI on October 6
Bharat Biotech was granted approval for conducting Covaxin trials in children back in May.(AP)
Bharat Biotech was granted approval for conducting Covaxin trials in children back in May.(AP)
Published on Oct 12, 2021 01:58 PM IST
Copy Link
By hindustantimes.com, Hindustan Times, New Delhi

India, Hungary agree to mutually recognise vaccine certificates; Serbia follows

The developments come a day after the UK government decided to remove the requirement of mandatory quarantine for vaccinated Indian passengers.
The ministry of external affairs said that the recognition of the vaccination certificates will cater to help people move across countries. (File Photo / AP)
The ministry of external affairs said that the recognition of the vaccination certificates will cater to help people move across countries. (File Photo / AP)
Published on Oct 09, 2021 07:46 AM IST
Copy Link
ANI |

WHO to take final decision on Covaxin nod next week

The approval could greatly influence how other countries treat people vaccinated with Covaxin manufactured by Bharat Biotech
A woman receives a dose of Covaxin manufactured by Bharat Biotech (REUTERS)
A woman receives a dose of Covaxin manufactured by Bharat Biotech (REUTERS)
Updated on Oct 06, 2021 02:49 AM IST
Copy Link
By Rhythma Kaul, Hindustan Times, New Delhi

WHO to decide on Covaxin emergency use listing next week

  • The World Health Organization said that Bharat Biotech has been submitting data on a rolling basis and submitted additional information at the WHO's request on September 27.
The Emergency Use Listing process is centred on determining if the vaccine is quality-assured, safe and effective, according to the WHO.(Sanchit Khanna/HT PHOTO)
The Emergency Use Listing process is centred on determining if the vaccine is quality-assured, safe and effective, according to the WHO.(Sanchit Khanna/HT PHOTO)
Published on Oct 05, 2021 08:54 PM IST
Copy Link
By hindustantimes.com | Written by Kunal Gaurav, Hindustan Times, New Delhi

WHO expert panel on vaccines to meet today, Covaxin on agenda

If Covaxin is included in the Emergency Use Listing (EUL), India's indigenously-developed Covid-19 vaccine will expectedly gain a wider global acceptance. 
Bharat Biotech's indigenous Covid-19 vaccine ‘Covaxin’. (File Photo / HT)
Bharat Biotech's indigenous Covid-19 vaccine ‘Covaxin’. (File Photo / HT)
Updated on Oct 05, 2021 07:10 AM IST
Copy Link
Written by Joydeep Bose | Edited by Meenakshi Ray

Bharat Biotech submits data from Covaxin's trials on children to DCGI: Report

The Hyderabad-based firm, last month, completed the jab's phase 2/3 trials for kids.
Bharat Biotech International Limited's Covaxin (HT File Photo)
Bharat Biotech International Limited's Covaxin (HT File Photo)
Published on Oct 03, 2021 10:24 AM IST
Copy Link
By hindustantimes.com | Written by Karan Manral, New Delhi

‘Next 6-8 weeks are important as…’: Guleria on how Covid cases can drop

AIIMS director Dr Randeep Guleria said that he is hopeful Covaxin will soon be able to receive the WHO nod and travelling overseas will become easier for those who have taken both shots of the coronavirus vaccine.
AIIMS director Dr Randeep Guleria said that he is “hopeful” the approval of Covaxin by the WHO should happen soon. (ANI Photo)
AIIMS director Dr Randeep Guleria said that he is “hopeful” the approval of Covaxin by the WHO should happen soon. (ANI Photo)
Updated on Oct 01, 2021 06:26 PM IST
Copy Link
Written by Sharangee Dutta | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

Working with WHO to get emergency use listing for Covaxin: Bharat Biotech

  • The company was responding to reports that said the grant of EUL could be delayed further as WHO had more technical queries regarding the inactivated whole virus vaccine.
Bharat Biotech is working with the World Health Organization (WHO) to obtain Emergency Use Listing for Covaxin, its Covid vaccine. (PTI)
Bharat Biotech is working with the World Health Organization (WHO) to obtain Emergency Use Listing for Covaxin, its Covid vaccine. (PTI)
Updated on Sep 29, 2021 03:13 AM IST
Copy Link
By Rhythma Kaul, New Delhi

‘Diligently working with WHO to obtain EUL at the earliest’, says Bharat Biotech

“As a responsible manufacturer with past approvals for our other vaccines, we do not find it appropriate to speculate or comment on the regulatory approval process and its timelines. We are diligently working with the WHO to obtain EUL at the earliest,” Bharat Biotech said.
Covaxin is one among the three vaccines being used in India's immunisation programme against Covid-19.(AP )
Covaxin is one among the three vaccines being used in India's immunisation programme against Covid-19.(AP )
Published on Sep 28, 2021 04:17 PM IST
Copy Link
Written by Srivatsan K C | Edited by Avik Roy, Hindustan Times, New Delhi

WHO's nod for Covaxin delayed again over technical queries: Reports

Covaxin manufacturer Bharat Biotech has said it has submitted all data required for clearance of the Covid-19 vaccine. 
Empty Covaxin vaccine vials are after theCovid-19 vaccination in Thane, (Praful Gangurde/HT File Photo)
Empty Covaxin vaccine vials are after theCovid-19 vaccination in Thane, (Praful Gangurde/HT File Photo)
Published on Sep 28, 2021 06:19 AM IST
Copy Link
By hindustantimes.com | Written by Meenakshi Ray, New Delhi

Court seeks Centre’s stand on cancer patient’s plea to take Covaxin as 2nd dose

The petitioner stated in his plea that he developed a severe reaction and was hospitalised for four days after receiving Covishield as the first dose of Covid-19 vaccine, and that he wants to take Covaxin as the second dose as per his doctor’s advice. 
Mixing one dose each of Covaxin and Covishield vaccine against Covid-19 has not received any official nod from the central government yet.
Mixing one dose each of Covaxin and Covishield vaccine against Covid-19 has not received any official nod from the central government yet.
Updated on Sep 27, 2021 05:42 PM IST
Copy Link
Written by Sharangee Dutta | Edited by Avik Roy, Hindustan Times, New Delhi

Bharat Biotech completes phase 2/3 trials of Covaxin in children

“Paediatric Covaxin just completed phase 2/3 trials. The data analysis is going on. We will be submitting the data by next week,” Bharat Biotech’s chairman and managing director Krishna Ella said.
Briefing on the production of Covaxin, Krishna Ella said that it would reach 55 million doses in October.(AP)
Briefing on the production of Covaxin, Krishna Ella said that it would reach 55 million doses in October.(AP)
Published on Sep 21, 2021 04:19 PM IST
Copy Link
Written by Srivatsan K C | Edited by Avik Roy, Hindustan Times, New Delhi

Covaxin's wait continues, WHO ‘delays’ emergency use nod till October 5

Bharat Biotech said on Friday that it has submitted all the data to WHO for emergency use listing (EUL) of Covaxin and is now awaiting feedback.
Bharat Biotech's Covaxin, India's first indigenous Covid-19 vaccine. (File Photo / AFP)
Bharat Biotech's Covaxin, India's first indigenous Covid-19 vaccine. (File Photo / AFP)
Published on Sep 18, 2021 07:43 AM IST
Copy Link
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi

Inappropriate to comment on WHO's Covaxin approval process: Bharat Biotech

  • Bharat Biotech said it has responded to all clarifications sought by the WHO following the submission of Covaxin’s clinical trial data for Emergency use Listing in early July.
The Phase 3 clinical trials data of Covaxin demonstrated 77.8 per cent efficacy.(Bloomberg)
The Phase 3 clinical trials data of Covaxin demonstrated 77.8 per cent efficacy.(Bloomberg)
Published on Sep 17, 2021 03:59 PM IST
Copy Link
By hindustantimes.com | Written by Kunal Gaurav, Hindustan Times, New Delhi

'Need more scientific data to clarify’: Centre on mixing of Covid-19 vaccines

The Drugs Controller General of India in August approved a proposal by the CMC Vellore, Tamil Nadu, to conduct a study to analyse the mixing of one dose each of Covaxin and Covishield doses.
The study on mixing of Covid-19 vaccines is being conducted with 300 volunteers who are administered a dose each of Covaxin and Covishield – the first two vaccines to receive the DCGI nod.
The study on mixing of Covid-19 vaccines is being conducted with 300 volunteers who are administered a dose each of Covaxin and Covishield – the first two vaccines to receive the DCGI nod.
Published on Sep 14, 2021 09:51 PM IST
Copy Link
Written by Sharangee Dutta | Edited by Avik Roy, Hindustan Times, New Delhi

WHO approval for Bharat Biotech’s Covaxin likely this week: Report

  • After receiving Bharat Biotech’s documentation WHO chief scientist Dr Soumya Swaminathan had said on July 9 that the final approval will be granted in four to six weeks.
Covaxin was found to be nearly 77.8% effective against symptomatic Covid-19 cases in final phase 3 trials, according to Bharat Biotech. (AP Photo/Bikas Das)(AP)
Covaxin was found to be nearly 77.8% effective against symptomatic Covid-19 cases in final phase 3 trials, according to Bharat Biotech. (AP Photo/Bikas Das)(AP)
Published on Sep 13, 2021 05:25 PM IST
Copy Link
By hindustantimes.com, Hindustan Times, New Delhi

How to identify fake Covid-19 vaccines? Centre issues guidelines

Covid-19 vaccines being used in the country's vaccination drive include the Serum Institute of India's Covishield, Bharat Biotech's Covaxin and the Russian vaccine Sputnik V.
As many as 684.6 million vaccine doses have been administered so far in the country. (File Photo)
As many as 684.6 million vaccine doses have been administered so far in the country. (File Photo)
Published on Sep 05, 2021 02:28 PM IST
Copy Link
By hindustantimes.com | Written by Meenakshi Ray, New Delhi

Mansukh Mandaviya rolls out Gujarat facility’s first Covaxin batch

The Chiron Behring Vaccines plant, a wholly-owned subsidiary of Bharat Biotech at Ankleshwar, has a production capacity of at least 10 million doses per month
Union health minister Mansukh Mandaviya releases the first commercial batch of Covaxin, at Ankaleshwar on Sunday. ANI
Union health minister Mansukh Mandaviya releases the first commercial batch of Covaxin, at Ankaleshwar on Sunday. ANI
Updated on Aug 29, 2021 11:49 PM IST
Copy Link
By Rhythma Kaul, New Delhi

News updates from HT: AIIMS doctor weighs in on schools reopening in Delhi

Here are today’s top news, analysis and opinion. Know all about the latest news and other news updates from Hindustan Times.
Representational image(PTI)
Representational image(PTI)
Updated on Aug 28, 2021 05:10 PM IST
Copy Link
By hindustantimes.com, New Delhi

Have you got one dose of Covaxin? ICMR study reveals how protected you are

If you have been infected before, then the response of one Covaxin shot is similar to that of two in persons never infected by Covid, the study said.
Taking both doses of any vaccine -- Covaxin, Covishield, Sputnik V-- is mandatory for the maximum protection against Covid-19.(AFP)
Taking both doses of any vaccine -- Covaxin, Covishield, Sputnik V-- is mandatory for the maximum protection against Covid-19.(AFP)
Published on Aug 28, 2021 03:48 PM IST
Copy Link
By hindustantimes.com | Written by Poulomi Ghosh

News updates from HT: Pfizer's Covid-19 vaccine receives full approval from FDA

Here are today’s top news, analysis, and opinion at 9pm. Know all about the latest news and other news updates from Hindustan Times.
Pfizer's Covid-19 vaccine (Reuters)
Pfizer's Covid-19 vaccine (Reuters)
Published on Aug 23, 2021 08:56 PM IST
Copy Link
By hindustantimes.com, New Delhi, Hindustan Times
SHARE
  • 1
  • 2
  • 3
  • ...
Story Saved
×
Saved Articles
My Reads
Sign out
New Delhi 0C
Tuesday, October 26, 2021